Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Meta and Apple team up to make Muse AI models run better on Macs

October 15, 2026

Calgary Stampeders need help to reach CFL playoffs

October 15, 2026

Flintstones vitamins, Aleve and Claritin tablets hit in new recall

October 15, 2026

Sony made a $5,900 gold-plated Walkman MP3 player

October 15, 2026

Fisheries sector fund gets $300 million extension from Ottawa, Atlantic provinces

October 15, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » China Diabetes Care Drugs Market to Reach USD 13.73 Billion by 2028, Propelled by Rising Prevalence and Advanced Treatment Options
Press Release

China Diabetes Care Drugs Market to Reach USD 13.73 Billion by 2028, Propelled by Rising Prevalence and Advanced Treatment Options

By News RoomJanuary 30, 20244 Mins Read
China Diabetes Care Drugs Market to Reach USD 13.73 Billion by 2028, Propelled by Rising Prevalence and Advanced Treatment Options
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) — The “China Diabetes Care Drugs Market Size & Share Analysis – Growth Trends & Forecasts (2023 – 2028)” report has been added to ResearchAndMarkets.com’s offering.

The China Diabetes Care Drugs Market is currently experiencing significant growth and is predicted to attain a valuation of USD 13.73 billion by 2028, ascending at a compound annual growth rate (CAGR) of 2.70% from 2023. The intensified focus on early intervention and management of diabetes, particularly in the face of the COVID-19 pandemic, has further highlighted the critical nature of diabetes care in China.

Oral Anti-Diabetic Drugs Dominate the Market
The oral anti-diabetic drugs segment has captured the highest market share this year and is anticipated to continue its upward trajectory at an estimated CAGR of 3.1% over the forecast period. One of the key drivers for this segment’s growth is the ease of administration and cost-effectiveness of oral anti-diabetic medication, which has led to improved patient adherence and demand. With China facing a substantial rise in the number of individuals diagnosed with diabetes, the demand for diabetic drugs has concurrently increased, signalling a robust market for these products.

The Emergence of GLP-1 Receptor Agonists as a Growth Catalyst
The Glucagon-like peptide-1 receptor agonist segment is forecasted to exhibit the highest growth rate in the market, with an expected CAGR of about 5.2% during the forecast period. The wide-ranging benefits of these medications, which include lower risk of hypoglycemia, weight loss, and cardiovascular advantages, make them a preferred option for diabetes management. Such factors, along with the proactiveness of the Chinese government through initiatives like the Healthy China 2030 Plan, are significantly contributing to the market’s expansion.

Regulatory Initiatives Propel Market Growth
The Chinese government’s efforts to tackle non-communicable diseases, including diabetes, through various initiatives have provided a favorable environment for the growth of the Diabetes Care Drugs Market. By promoting regular monitoring and effective disease management, the government aims to enhance the overall health outcomes for diabetes patients and reduce early mortality rates associated with the condition.

  • Competitive Landscape: The competitive landscape in the China Diabetes Care Drugs Market denotes a moderate level of fragmentation with key players like Eli Lilly, Sanofi, and Novo Nordisk, alongside a diverse array of generic manufacturers, collectively shaping the dynamics of the market.
  • Focus on Primary Care: To address the rising demand and enhance the efficiency of the healthcare system, there is a growing emphasis on strengthening primary care facilities and health promotion, which is likely to be beneficial for diabetes control.

Implications for the Healthcare Industry
The uptrend in the China Diabetes Care Drugs Market carries implications for stakeholders across the healthcare industry. Pharmaceutical companies, healthcare providers, and policymakers must adapt to the evolving market landscape, which is characterized by increasing demand for innovative and effective diabetes management solutions. As the market continues to grow, its influence is expected to reverberate across global healthcare markets, echoing the importance of diabetes care as a pivotal component of public health strategies. For more insights into the China Diabetes Care Drugs Market and its growth prospects, readers can access the comprehensive analysis included in the latest research publication on this rapidly expanding sector.

A selection of companies mentioned in this report includes

  • Takeda
  • Novo Nordisk A/S
  • Pfizer
  • Eli Lilly and Company
  • Janssen Pharmaceuticals
  • Astellas
  • Boehringer Ingelheim
  • Merck and Co.
  • AstraZeneca
  • Bristol Myers Squibb
  • Novartis
  • Sanofi Aventis

For more information about this report visit https://www.researchandmarkets.com/r/97ossg

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  • China Diabetes Drugs Market China Diabetes Care Drugs Market Volume C A G R By Drugs 2023 2028

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

vineyard vines Returns as Official Style of the Head Of The Charles® Regatta

Bigger & Better Than Ever: Laxmi & Chef Kunal Kapur Return With ‘Diwali Delights’ Season 2

2026 Chery International User Summit to Kick Off: LUXEED Set for Global Brand Launch

Going Asset Management Wins Capital’s Excellence Fund Award, Harnessing Technology to Enhance the Long-Term Value of Assets

Alation Honors 2026 AI Radicals Award Winners at revAlation

Supported Employment: Helping Individuals Build Meaningful Careers

“The Carbon Pursuit of Happiness” Premieres October 10: A New Chapter for In-Depth Dialogue on Health and Humanity

Evolution Metals & Technologies Corp. Raises Fiscal 2026 Revenue Guidance 62% at Midpoint to 11 Million and Reaffirms 460 Million Fiscal 2027 Outlook

Ufunded Launches “Spotlight” Series, Documenting the Minds Shaping Modern Trading

Editors Picks

Calgary Stampeders need help to reach CFL playoffs

October 15, 2026

Flintstones vitamins, Aleve and Claritin tablets hit in new recall

October 15, 2026

Sony made a $5,900 gold-plated Walkman MP3 player

October 15, 2026

Fisheries sector fund gets $300 million extension from Ottawa, Atlantic provinces

October 15, 2026

Latest News

Friends don’t let friends feed their data to AI agents

October 15, 2026

As bond yields rise, how to pick between a variable or fixed rate mortgage?

October 15, 2026

Carney says he expects nations, including U.S., to stay out of Alberta vote

October 15, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version